Medicamen Biotech Hits 52-Week Low, Underperforms Market with -36.42% Return in Past Year

Medicamen Biotech, a microcap pharmaceutical company, has recently hit a 52-week low on March 13, 2024. The stock has been underperforming in the market, with a 'Sell' call from MarketsMOJO. Today, the stock touched a new low of Rs. 391, showing a -2.55% underperformance compared to the sector.

In the past three days, the stock has been on a downward trend, with a -17% return during this period. The intraday low for the stock was Rs. 391, a decrease of -3.41%. Additionally, Medicamen Biotech is currently trading below its 5-day, 20-day, 50-day, 100-day, and 200-day moving averages.

Compared to the Sensex performance of 26.35%, Medicamen Biotech has shown a -36.42% return in the past year. This indicates a significant underperformance by the company in the market.

Despite these recent developments, it is important to note that this article is not making any recommendations or discussing potential future growth. It is simply stating the facts and figures of Medicamen Biotech's current performance in the market. Investors should conduct their own research and analysis before making any investment decisions.